News | Tomotherapy | May 19, 2020

Accuray Synchrony Wins 2020 MedTech Breakthrough Award

Annual awards program recognizes outstanding health and medical technology products and companies

May 19, 2020 — Accuray Incorporated announced that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected the Accuray Synchrony Real-time Adaptive Technology for the Radixact System as the winner of its "Best Overall Medical Device Solution" award in the fourth annual MedTech Breakthrough Awards program.

The Radixact System, the next-generation TomoTherapy platform, is a radiotherapy system designed to provide oncology clinical teams with the imaging capabilities, treatment flexibility and precise dose delivery they had come to expect with its predecessor device, with the addition of components that can significantly enhance interoperability and increase patient throughput.

Originally developed to expand on the Accuray CyberKnife System's unique automatic motion tracking and synchronization capabilities, Synchrony for the Radixact System is designed to adapt for tumors that move as a result of bodily processes, including respiration and digestion, as well as patient movement. Some tumors may be located in areas of the body that move regularly, such as the lungs. Also, filling of the bladder, gas in the bowel or even slight patient movements can shift the tumor target by a millimeter or more.

Tracking tumor movement — and synchronizing precise treatment delivery with that movement using the Accuray Synchrony Real-time Adaptive Technology — helps to maximize treatment effectiveness and minimize dose to surrounding tissues. The beams of radiation are delivered continuously throughout the treatment session as the patient breathes naturally. In comparison, gating methods deliver radiation only when the tumor is close to the expected location and pause treatment delivery when the moving tumor is outside of the "treatment window." This lengthens the time the patient needs to be on the treatment table.

"Cancer is increasingly being managed as a chronic condition. With this will be a corresponding rise in the use of radiation therapy, and a need for technology that can precisely and accurately treat each patient's unique tumor," said Joshua H. Levine, president and CEO at Accuray. "Our one-of-a-kind, artificial-intelligence driven Synchrony software combined with the Radixact System delivers a breakthrough in precision radiation therapy treatments. Synchrony is the only technology that uses image guidance to automatically adapt and synchronize the radiation beam to the position of the tumor if and when it moves during treatment. When used with the Radixact System, it facilitates the efficient and effective delivery of both hypofractionated and standard radiation therapy, making it easier for clinical teams to provide treatments tailored to meet each individual patient's needs."

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year's program attracted more than 3,750 nominations from over 15 different countries throughout the world.

"The Synchrony Real-time Adaptive Technology for the Radixact System embodies the spirit of the MedTech Breakthrough Awards program by delivering a true breakthrough for cancer patients and the clinicians who treat them," said James Johnson, managing director, MedTech Breakthrough. "Accuray has developed a powerful portfolio of advanced technology solutions that is revolutionizing radiation therapies for patients, minimizing the amount of healthy tissue exposed to high-dose radiation and, ultimately, helping to improve patient outcomes. We are thrilled to award Accuray with the marquee "Best Overall Medical Device Solution" designation for their breakthrough technology that is strengthening and advancing the toolkit for cancer-fighting solutions. Congratulations to the entire Accuray team on their well-deserved industry recognition with this 2020 MedTech Breakthrough award."

For more information:

Related Content

Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer
The results of an online questionnaire of 609 breast cancer survivors in the U.S. suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic.

Getty Images

News | Coronavirus (COVID-19) | August 19, 2020
August 19, 2020 — The...
Smoking is strongly linked to lower use of cancer screening services by women, and more advanced disease once cancer is diagnosed, reveals research published in the online journal BMJ Open.

Getty Images

News | Lung Imaging | August 14, 2020
August 14, 2020 — Smoking is strongly linked to lower use of...
Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.